Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Narcolepsy with co-occurring epilepsy: diagnostic pitfalls and management strategy.

Therapeutic advances in neurological disorders·2026
Same author

Cross-cultural validation of the International Classification of Cognitive Disorders in Epilepsy (IC-CoDE) in Chinese-speaking people with epilepsy.

Seizure·2026
Same author

Molecular and clinicopathological characterisation of SMARCA4-deficient uterine tumours: distinguishing features between dedifferentiated/undifferentiated endometrial carcinoma and undifferentiated uterine sarcoma.

Pathology·2026
Same author

MCM-UNet++: A Hybrid Soft Computing Framework for Multi-Scale Polyp Segmentation via Enhanced Global Context and Adaptive Feature Fusion.

Sensors (Basel, Switzerland)·2026
Same author

Comprehensive genome-wide mining and characterization of the NAC transcription factor family in Gynostemma pentaphyllum identifies GpNAC68 as a positive regulator of drought tolerance in transgenic Arabidopsis.

BMC plant biology·2026
Same author

Perceived organizational support as a mediator between role clarity and work engagement among neurology specialist nurses: a cross-sectional study.

BMC nursing·2026

相关实验视频

Updated: Jan 10, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.2K

解码UTROSCT异质性:系统的临床病理学评估与分子分析相结合.

Jing Yang1, Jinku Zhang2,3, Jinmei Li2

  • 1Department of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University, Beijing, PR China.

The journal of pathology. Clinical research
|November 29, 2025
PubMed
概括

类似卵巢性带瘤 (UTROSCT) 的子宫瘤可能具有攻击性. 转移性病变中的拷贝数变化 (CNVs),如SMARCB1和ATRX损失,驱动UTROSCT进展和转移.

关键词:
在SMARCB1中,在 SWI/SNF 中.乌托罗斯克特 (UTROSCT) 是一个副本编号变化 副本编号变化预后 预后 预后

更多相关视频

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.0K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K

相关实验视频

Last Updated: Jan 10, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.2K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.0K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K

科学领域:

  • 妇科病理学的病理学
  • 在瘤学瘤学.
  • 分子病理学分子病理学

背景情况:

  • 类似卵巢性带瘤的子宫瘤 (UTROSCT) 是一种罕见的子宫瘤.
  • 虽然通常是良性的,但一个子集表现出具有复发和转移的侵略性行为.
  • 复杂的融合基因是UTROSCT.中关键的分子驱动因素.

研究的目的:

  • 研究UTROSCT的临床病理学和分子特征.
  • 为了确定UTROSCT中复发和转移的预测因素.
  • 探索在UTROSCT中转移性进展的遗传基础.

主要方法:

  • 通过融合基因检测对25例UTROSCT病例的分子确认.
  • 综合临床病理学,免疫组织化学和分子分析.
  • 多组体分析比较初级和转移性UTROSCT瘤.

主要成果:

  • 确定了经常发生的融合基因:ESR1::NCOA3,GREB1::NCOA1,ESR1::NCOA2,GREB1::NCOA2,GREB1::SS18,GREB1::CTNNB1.
  • 瘤大小>5厘米,FIGO阶段IB和LVSI是复发/转移的独立预测因素.
  • 转移性UTROSCT显示出独特的副本数变异 (CNVs),包括SMARCB1和ATRX损失,在初级瘤中不存在.

结论:

  • 融合基因检测对于UTROSCT诊断至关重要.
  • 瘤大小和阶段等临床因素可以预测UTROSCT的攻击性.
  • CNVs,特别是SWI/SNF复杂失调,涉及UTROSCT转移能力,代表了一种新的致癌机制.